In stage IV unresectable CRC, lack of CDX2 expression predicted poor survival.46 Moreover, lack of CDX2 expression was proposed as a poor prognostic and predictive biomarker for the response to chemotherapy in stages II and III CRC.47 Consistently, our data indicated that reduced CDX2 correlated with worse OS and RFS of patients with CRC. The gene discussed is CDX2; the disease is colorectal carcinoma.